
• Reported GAAP EPS of $0.17 up 137.78% YoY • Reported revenue of $92.02M up 3054.65% YoY
Bullish
Liquidia achieved YUTREPIA net product sales of $148.3M for 2025, recorded its second profitable quarter, and ended 2025 with $190.7M cash, supporting pipeline advancement.
Bearish
Liquidia faces increased SG&A expenses of $75.6M and higher other expenses from borrowings, alongside ongoing litigation risk from United Therapeutics that could block YUTREPIA sales.